Clinical Trial Update: Effect of Hypoxia on FMISO PET to Response to Lu-177 PSMA Treatment [NA]

View source ↗

Summary

A clinical trial update investigating whether hypoxia assessed by FMISO PET predicts response to Lu-177 PSMA therapy in prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Fluoromisonidazole (FMISO) (fluoromisonidazole)
• Lu-177 PSMA-617 (Pluvicto) (Lutetium-177 PSMA-617)

Snippet

Sponsor: Cigdem Soydal | Conditions: Prostatic Neoplasms, Hypoxia | NA | Status: RECRUITING